Novartis shares fall as profit lags estimates; downside from Entresto patent loss to continue

Core Viewpoint - Novartis reported third-quarter profitability that fell below market expectations, leading to a 3.3% decline in shares during pre-market trading [1] Financial Performance - The company experienced higher sales from key medications, but overall profitability did not meet market forecasts [1]